Raymond James & Associates Bristol Myers Squibb CO Call Options Transaction History

Raymond James & Associates

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Jul 19, 2024	BUY	$40.25 - $52.99 $1.73 Million - $2.28 Million	43,000 New	43,000 $1.79 Million
Q4 2023 Jan 16, 2024	BUY	$48.48 - $57.85 $363,600 - $433,875	7,500 New	7,500 $384,000
Q4 2022 Feb 08, 2023	BUY	$68.48 - $81.09 $1.39 Million - $1.65 Million	20,300 New	20,300 $1.46 Million
Q1 2022 May 11, 2022	SELL	$61.48 - $73.72 $4.94 Million - $5.92 Million	-80,300 Reduced 88.14%	10,800 $50,000
Q4 2021 Feb 08, 2022	BUY	$53.63 - $62.52 $493,396 - $575,184	9,200 Added 11.23%	91,100 $122,000
Q3 2021 Nov 02, 2021	BUY	$59.17 - $69.31 $118,340 - $138,620	2,000 Added 2.5%	81,900 $37,000
Q2 2021 Aug 11, 2021	BUY	$61.91 - $67.42 $3.31 Million - $3.6 Million	53,400 Added 201.51%	79,900 $73,000
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $231,426 - $260,285	3,900 Added 17.26%	26,500 $49,000
Q4 2020 Feb 12, 2021	SELL	$57.74 - $65.43 $1.93 Million - $2.19 Million	-33,400 Reduced 59.64%	22,600 $7,000
Q3 2019 Nov 07, 2019	BUY	$42.77 - $50.71 $2.4 Million - $2.84 Million	56,000 New	56,000 $55,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $120B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.